Intended for licensed healthcare professionals located in Switzerland.

Waterfall with bar chart over the top Waterfall
orange diamonds

What is PEMAZYRE®?

PEMAZYRE is indicated as monotherapy for the treatment of adults with locally advanced, unresectable or metastatic cholangiocarcinoma with fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement, that have progressed after at least one line of systemic therapy (see the “Clinical efficacy” section of the Swiss Professional Information).a

FGFR2 fusion positivity status must be confirmed prior to initiation of PEMAZYRE therapy. Assessment for FGFR2 fusion positivity in tumour specimens should be performed with a validated diagnostic test.

Pemigatinib is a kinase inhibitor of FGFR1, 2 and 3. It inhibits FGFR phosphorylation and signalling and decreases cell viability in cells expressing FGFR genetic alterations, including point mutations, amplifications, and fusions or rearrangements.

aDue to incomplete clinical data at the time of review of the marketing authorisation application, the medicinal product PEMAZYRE is authorised for a limited period of time (Art. 9a LPTh). The temporary authorisation must be linked to the timely satisfaction of conditions. Once these conditions are met, the temporary authorisation may be converted into ordinary authorisation.

Reference:
PEMAZYRE® (pemigatinib). Swiss Professional Information, June 2021; https://www.swissmedicinfo.ch/ (accessed 31 August 2021).

DNA Helix

About PEMAZYRE

Learn more about the clinical data on PEMAZYRE

Discover more

Medical book

FGFR2 fusion testing

Discover about FGFR2 fusions in patients with CCA

Discover more

Click and pill

Dosing and administration

Learn more about the dosing and administration schedule of PEMAZYRE

Discover more

Incyteful Platform

Incyteful for you

An Incyte platform that offers medical education relevant to your daily practice. Easy to access, personalised content that fits with your schedule.

Incyteful is your one-stop resource for updates about the disease areas and Incyte's approved products that you care about.

Coming soon

PEMAZYRE self-directed learning

A self-directed learning material to complete in your own time. With the PEMAZYRE learning module, you can learn about the unmet needs in CCA, discuss the need for molecular profiling for early patient identification and learn more about PEMAZYRE.

Learn about PEMAZYRE

PEMAZYRE eDetail